Lyndra Therapeutics

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Novartis To Pay Argo $185m Up Fron

Through years of private equity fund raises and partnerships, Lyndra Therapeutics has been building up its strategy to bring once-weekly or monthly oral medications to the health care system. With a

Gamida Cell is nearing an expected US approval of its “breakthrough” allogeneic hematopoietic stem cell transplant (allo-HSCT) therapy omidubicel – but a lack of money could undermine its chances of

Biopharmaceutical companies are entitled to set a path forward and then change course, just like anyone else, so it should not come as a surprise that Sirnaomics, Inc. reassessed its financing optio